Leila Alland is Chief Medical Officer at PMV Pharmaceuticals, Inc. (PMVP). They have made 11 open-market trades across 2 companies since 2021, most recently 2026-06-30.
CIK 0001825216
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $52K since 2024, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABEO | 162,614 | $722K |
| PMVP | 45,909 | $56K |
| Total | $778K |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABEO | SELL | 2026-06-30 | 2026-07-02 | $5.92 | $65K | +13.2% | -0.9% | -18.5% |
| ABEO | SELL | 2026-02-02 | 2026-02-02 | $5.09 | $92K | -3.5% | -3.9% | +15.0% |
| ABEO | BUY | 2024-05-16 | 2024-05-20 | $4.71 | $52K | -2.9% | +0.2% | +16.0% |
| ABEO | SELL | 2023-09-27 | 2023-09-29 | $3.90 | $28K | -0.2% | -11.2% | +20.4% |
| PMVP | SELL | 2023-09-15 | 2023-09-18 | $6.62 | $42K | -1.6% | -65.8% | -64.4% |
| PMVP | SELL · 10b5-1 | 2021-09-09 | 2021-09-10 | $30.25 | $3K | -7.2% | -16.5% | -24.0% |
| PMVP | SELL | 2021-09-07 | 2021-09-08 | $30.25 | $118K | -5.8% | -8.0% | -17.3% |
| PMVP | SELL | 2021-08-09 | 2021-08-10 | $33.97 | $296K | -17.9% | -16.7% | -28.4% |
| PMVP | SELL | 2021-07-07 | 2021-07-08 | $32.30 | $258K | +10.1% | +10.0% | -11.3% |
| PMVP | SELL | 2021-06-07 | 2021-06-08 | $33.52 | $222K | +2.1% | -3.8% | -13.6% |
| PMVP | SELL | 2021-05-07 | 2021-05-10 | $34.81 | $273K | +5.2% | -2.7% | +4.4% |
| PMVP | SELL | 2021-04-07 | 2021-04-08 | $33.86 | $270K | -9.1% | +1.3% | -6.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.